Payment overview · 2025
General Payments
$1,448.98
47 reported records · 18 companies
Healthcare provider profile · identity verified
Corattur Natesa Natesan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, OH · NPI 1790770568
Verified facts
What the public records show
CMS Open Payments records show Corattur Natesa Natesan, MD received $1,448.98 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEFLARO as an associated drug or biological on 11895 records involving 6021 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Teflaro by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $352.32 | 24.3% | 12 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $309.16 | 21.3% | 2 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $143.82 | 9.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.70 | 9.7% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $130.71 | 9.0% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $82.23 | 5.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.35 | 3.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $39.19 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.02 | 2.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.45 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.07 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.21 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.63 | 1.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $19.55 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.85 | 1.2% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $16.25 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.89 | 1.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,448.98 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $309.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $235.56 | 6 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $143.82 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $130.71 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $82.23 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | TEFLARO open payments reported associated product |
CMS Open Payments — General Payments 11895 supporting records · 6021 recipient NPIs · example record 1201352826 |
Teflaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
461 | 45 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
461 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 878 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 118 |
| Eliquis | Apixaban | 461 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 409 | 85 |
| Gabapentin | Gabapentin | 403 | 61 |
| Lisinopril | Lisinopril | 374 | 74 |
| Furosemide | Furosemide | 310 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 32 |
| Sertraline Hcl | Sertraline Hcl | 223 | 23 |
| Donepezil Hcl | Donepezil Hcl | 207 | 21 |
| Omeprazole | Omeprazole | 202 | 40 |
| Potassium Chloride | Potassium Chloride | 200 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 44 |
| Losartan Potassium | Losartan Potassium | 196 | 51 |
| Metformin Hcl | Metformin Hcl | 177 | 40 |
| Carvedilol | Carvedilol | 174 | 27 |
| Allopurinol | Allopurinol | 162 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 39 |
| Mirtazapine | Mirtazapine | 148 | 18 |
| Famotidine | Famotidine | 138 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 23 |
| Spironolactone | Spironolactone | 116 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 23 |
| Divalproex Sodium | Divalproex Sodium | 109 | 22 |
| Torsemide | Torsemide | 106 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 105 | 19 |
| Montelukast Sodium | Montelukast Sodium | 100 | 15 |
| Prednisone | Prednisone | 100 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 17 |
| Xarelto | Rivaroxaban | 86 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 80 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 11 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 15 |
| Farxiga | Dapagliflozin Propanediol | 73 | suppressed |
| Levetiracetam | Levetiracetam | 73 | suppressed |
| Jardiance | Empagliflozin | 72 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 11 |
| Finasteride | Finasteride | 65 | 15 |
| Trazodone Hcl | Trazodone Hcl | 65 | 17 |
| Baclofen | Baclofen | 63 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 29 |
| Risperidone | Risperidone | 59 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 56 | 17 |
| Glipizide | Glipizide | 55 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 49 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 48 | suppressed |
| Simvastatin | Simvastatin | 47 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Lacosamide | Lacosamide | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Creon | Lipase/Protease/Amylase | 36 | suppressed |
| Haloperidol | Haloperidol | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 15 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Zonisade | Zonisamide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | 15 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Budesonide | Budesonide | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Klayesta | Nystatin | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 11 |
| Teflaro | Ceftaroline Fosamil Acetate | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Cabergoline | Cabergoline | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Entacapone | Entacapone | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Morphine Sulfate | Morphine Sulfate | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humira | Adalimumab | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,448.98 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, BRILINTA, CAMZYOS, Dexcom G6 Transmitter, FARXIGA, Fibroscan, GVOKE HYPOPEN, LEQVIO, Ozempic, PROVENGE, REXULTI, Rybelsus, SYNERGY ABLATION SYSTEM, ULTOMIRIS, VRAYLAR, VYNDAQEL, WATCHMAN Access System, ZENPEP, ZORYVE, iTIND System | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error